Plasma neurofilament light links mortality to neuroaxonal injury beyond clinical decline and Alzheimer disease plasma biomarkers: a multi-cohort study of oldest old individuals

Blood-based neurofilament light (NfL) is associated with all-cause mortality, but whether this reflects neuroaxonal injury or overlaps with cognitive and functional decline remains unclear. We followed 559 individuals aged 92-107 from three oldest-old cohorts for up to 16 years: cognitively healthy Dutch centenarians and two population-based Danish cohorts. Plasma biomarkers (A{beta}42/40, A{beta}40, A{beta}42, pTau-181, pTau-181/A{beta}42, NfL, and GFAP; Dutch cohort; NfL, Danish cohorts), cognition, and activities of daily living (ADL) were evaluated against mortality. NfL was the only biomarker consistently associated with mortality (HR 1.21-1.38), whereas AD-specific biomarkers did not predict mortality despite reflecting post-mortem AD neuropathology. NfL remained associated with mortality independently of cognition and ADL; ADL mediated 13-21% across cohorts and cognition 28%, only where cognitive impairment was widespread. Mortality at extreme age is more closely linked to neuroaxonal injury than to upstream AD pathology, with NfL capturing biological vulnerability beyond cognitive and functional decline.